LMAN1

Across TCGA pan-cancer cohorts, LMAN1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LMAN1 data layer compared with 29 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LMAN1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LMAN1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, GBM, and LSCC are the cancer types where LMAN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.202	0.985	.007	30	view →
GBM	DFS	Quartile	All	0.710	0.879	.018	9	view →
LSCC	DFS	Median	All	0.884	0.985	.025	9	view →
LUAD	DFS	Median	III,IV	0.916	0.597	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LMAN1–CCRCC (OS)

Open the CCRCC breakdown →